Clinical trial
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast…
NCT00320411 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00320411 |
|---|---|
| Title | GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer |
| Official title | Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | lapatinib |
| Enrollment | 62 |
| Start date | Nov 28, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | May 3, 2006 |
| Last update posted | Jan 31, 2019 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: